Approved Biosimilar Products | Amgen Biosimilars

FDA-Approved Biosimilar Products

Please click the links below to download PDF versions of the following documents:


AMJEVITA™ Prescribing Information

AMJEVITA™ Medication Guide

AMJEVITA™ Patient Instructions for Use

This is not an offer for sale. AMJEVITA™ is currently not available commercially and will not be commercially available in the United States until on or after January 31, 2023.

Information for Healthcare Professionals

Healthcare professionals can visit, call the Amgen Medical Information hotline (800-77-AMGEN), or email to request medical information and to report an adverse event or product complaint.

Information for Patients

Click the button below to sign up to receive updates about Amgen Biosimilars. To learn more about what biosimilars are, visit our page for patient education on biosimilars.